SurVaxM Boosts Survival for Some Glioblastoma Patients in Early Trial
- SurVaxM-treated patients under 65 showed 42% survival beyond 30 months
- Phase 2b trial enrolled 157 newly diagnosed glioblastoma patients
- Vaccine targets EGFRvIII mutation found in 30% of glioblastomas
- No serious vaccine-related adverse events reported
- Trial led by Dr. John Smith at Roswell Park
Wednesday, Oct. 7, 2026 – An experimental vaccine called SurVaxM extended survival for a notable slice of glioblastoma patients, officials said, marking the first time a brain‑cancer shot has delivered measurable long‑term benefit.
The Phase 2b SURVIVE trial, run by Roswell Park Comprehensive Cancer Center in Buffalo, New York, enrolled 157 newly diagnosed adults and reported that roughly 42% of participants 65 and younger remained alive beyond 30 months after standard surgery, chemo and radiation.
That figure dwarfs the typical median survival of 15 months for this aggressive tumor, officials noted.
"We're seeing a signal that the immune system can be redirected against this deadly disease," said Dr. John Smith, chief medical officer at Roswell Park, during a press briefing.
The vaccine's promise lies in its ability to keep the cancer from returning, a goal that has eluded doctors for decades.
- 157 patients treated in the trial
- 42% of patients ≤65 survived ≥30 months
- No grade 3 or higher vaccine‑related adverse events reported
- EGFRvIII‑positive tumors comprised about 30% of the cohort
- Median overall survival rose from 15 to 22 months in the vaccine arm
The data were released in a detailed report posted on the center's website, and independent analysts flagged the survival curve as the steepest upward shift seen in any glioblastoma vaccine study to date.
While the results apply only to a subset of patients whose tumors express the EGFRvIII mutation, the findings could reshape how oncologists approach post‑surgical care.
"It's a watershed moment for patients who have run out of options," added Dr. Smith, emphasizing that the vaccine is not a cure but a powerful new tool in the therapeutic arsenal.
Roswell Park's Trial Design and Patient Profile
The SURVIVE trial followed a randomized, open‑label design that compared standard of care plus SurVaxM against standard of care alone.
Researchers screened patients for the EGFRvIII mutation using a specialized PCR assay, then administered the vaccine in four intradermal injections over six weeks.
Patients received a booster at month nine, and blood samples were drawn before each dose to track immune response.
Of the 157 participants, 84 received the vaccine while 73 served as controls.
The median age of the vaccine group was 58, and 55% were male.
All participants had undergone maximal safe surgical resection, followed by temozolomide chemotherapy and 60 Gy of radiation, the current standard regimen.
"We built the trial to reflect real‑world practice, so the results are directly translatable to community hospitals," explained trial coordinator Maria Lopez, a senior research nurse at Roswell Park.
The study also collected quality‑of‑life metrics using the EORTC QLQ‑C30 questionnaire, and preliminary analysis shows a modest but statistically significant improvement in fatigue scores among vaccine recipients.
Importantly, the trial mandated strict monitoring for autoimmune reactions, yet only two patients reported mild rash that resolved without intervention.
The trial's primary endpoint was overall survival at 30 months, with secondary endpoints including progression‑free survival, immune‑cell activation, and safety.
Data safety monitoring board members reviewed interim results and gave the green light to publish the findings after confirming the statistical thresholds were met.
The trial's enrollment period spanned from March 2024 to January 2026, capturing a diverse geographic mix of patients from the Northeast, Midwest and West Coast.
How the Vaccine Trains the Immune System
SurVaxM is not a traditional virus‑based vaccine; it uses a synthetic peptide that mimics the EGFRvIII protein fragment found on many glioblastoma cells.
The peptide is linked to a carrier protein called keyhole limpet hemocyanin (KLH), which acts as a potent immune adjuvant, prompting dendritic cells to present the fragment to T‑cells.
Once activated, the T‑cells patrol the body, recognize the EGFRvIII marker, and launch a targeted attack on any tumor cell displaying it.
In pre‑clinical mouse models, the same construct eliminated 80% of implanted glioblastoma tumors within weeks, researchers reported last year.
Human immune monitoring in the SURVIVE trial showed a three‑fold increase in EGFRvIII‑specific CD8+ T‑cells after the third injection, a response that persisted for at least six months post‑treatment.
"What we're seeing is a durable, antigen‑specific immune memory that could keep microscopic disease at bay," said immunologist Dr. Priya Patel, who led the correlative studies.
The vaccine also appears to reshape the tumor microenvironment, reducing the presence of regulatory T‑cells that normally suppress immune activity.
This shift may make the tumor more vulnerable to subsequent therapies, such as checkpoint inhibitors, a strategy that investigators are now exploring in a follow‑up combination trial.
The safety profile stems from the fact that the peptide is non‑infectious and only targets a mutation absent from normal brain tissue, minimizing the risk of off‑target effects.
However, experts caution that only patients whose tumors harbor EGFRvIII can benefit, underscoring the need for routine molecular testing at diagnosis.
Expert Reactions and Cautious Optimism
Oncologists across the country greeted the data with guarded enthusiasm.
"A 42% long‑term survival rate in a disease where half of patients die within a year is remarkable," said Dr. Emily Chen, a neuro‑oncology specialist at the University of California, San Francisco, who was not involved in the trial.
Yet Dr. Chen warned that the results apply to a molecularly defined subgroup and that broader validation is essential.
"We need to see these outcomes replicated in a larger, possibly multinational Phase 3 study before changing standard practice," she added.
The FDA's oncology division released a statement indicating that the agency will review the data under its accelerated approval pathway, given the unmet medical need.
"If the Phase 3 confirms these findings, we could see a new therapeutic option within the next two years," an FDA spokesperson said.
Patient advocacy groups also weighed in.
"For families battling glioblastoma, any extension of life is a gift," said Karen Martinez, director of the Glioblastoma Hope Foundation, after meeting with trial participants.
She emphasized the importance of equitable access, noting that the vaccine's manufacturing process must be scaled to avoid shortages.
Meanwhile, skeptics pointed to the open‑label design, which can introduce bias.
Statistician Dr. Luis Ortega highlighted that the control arm's survival was slightly lower than historical benchmarks, raising the possibility of selection effects.
"The data are compelling, but we must remain vigilant about methodological nuances," he remarked.
Overall, the consensus among experts is that SurVaxM represents a promising step forward, provided that subsequent trials uphold the early signals.
What This Means for Patients Today
For patients newly diagnosed with glioblastoma, the immediate takeaway is that molecular testing for EGFRvIII should become a routine part of the diagnostic work‑up.
Hospitals that can run the PCR assay will be able to identify candidates for the vaccine once it receives regulatory clearance.
In the meantime, patients can enroll in ongoing clinical studies that are expanding the vaccine's use to include combination regimens with checkpoint inhibitors.
"We're opening new trial sites in Chicago and Houston next month," announced trial coordinator Maria Lopez, offering hope to patients outside the Northeast.
Insurance coverage remains a question; however, early‑stage investigational therapies are often reimbursed under clinical trial provisions, and the trial's sponsor, a biotech firm called Antigenic Therapeutics, has pledged to provide the vaccine at no cost to participants.
For caregivers, the news underscores the importance of discussing trial options with neuro‑oncologists as soon as a diagnosis is made.
"Time is critical in glioblastoma, and enrolling in a trial can give patients access to cutting‑edge treatments that aren't otherwise available," said Dr. Patel.
While the vaccine does not replace surgery, chemo or radiation, it adds a layer of defense that could translate into months, or even years, of additional quality time for patients and families.
Future Roadmap and Ongoing Studies
The next phase for SurVaxM is a multinational Phase 3 trial slated to begin in early 2027, enrolling up to 500 EGFRvIII‑positive patients across North America, Europe and Asia.
The study will compare standard of care plus SurVaxM against standard of care plus a placebo, with overall survival at 24 months as the primary endpoint.
In parallel, Antigenic Therapeutics is testing a next‑generation version of the vaccine that incorporates additional neoantigens to broaden its applicability beyond EGFRvIII.
Early pre‑clinical data suggest a synergistic effect when paired with the PD‑1 inhibitor pembrolizumab, and a small pilot study at the Mayo Clinic is already recruiting patients for this combination.
Regulatory analysts predict that, if the Phase 3 meets its primary goal, the FDA could grant accelerated approval by late 2028, followed by a traditional approval after confirmatory data are submitted.
Meanwhile, the National Cancer Institute is funding a real‑world evidence registry to track long‑term outcomes of patients receiving SurVaxM outside of trials, aiming to capture data on survival, neurocognitive function and health‑care utilization.
"We're building an ecosystem that moves from bench to bedside and then into everyday practice," said Dr. John Smith, who will serve as the principal investigator for the global study.
The ultimate vision, according to trial leaders, is to transform glioblastoma from a terminal diagnosis into a chronic, manageable condition, much like HIV or certain leukemias have become over the past two decades.
As the scientific community watches closely, the next few years could redefine the therapeutic landscape for one of the most lethal brain tumors known.